SLC5A2 and dementia: A lower all-cause dementia risk associated with SGLT2 inhibitors was found among those with atherosclerotic cardiovascular disease (HR [95% CI]: 0.80 [0.68–0.95]) and renal insufficiency (HR [95% CI]: 0.80 [0.65–0.99]).